利伐沙班好用吗？

Rivaroxaban is also called Xarelto. Its main ingredient is rivaroxaban. Rivaroxaban is a highly selective oral drug that directly inhibits factor Xa. The main clinical indications are: 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Indicated to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. Today we will find out whether rivaroxaban is useful?

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants.

A newly published study shows that the new anticoagulant drug rivaroxaban from Bayer Healthcare of Germany can effectively reduce the formation of venous thrombosis in patients after major orthopedic surgery, and its efficacy is better than the current standard treatment of enoxaparin.

An international scientific research team published a paper in the journal "The Lancet" stating that through analysis of data from a multi-center, randomized, double-blind clinical trial called "BECORD4", among a total of more than 3,000 patients, researchers confirmed that compared with standard therapy using enoxaparin, patients treated with rivaroxaban reduced the risk of venous thromboembolism after orthopedic surgery by about one-third. "This is the first oral anticoagulant drug with better efficacy than the current standard therapy, so it may become a new clinical treatment option for preventing severe blood clots after major orthopedic surgery," said Professor A. Turpai from McMaster University in Canada. "At the same time, this new drug also has good economics."

The above is the content of the effects of rivaroxaban, I hope it can help you!